Spinal Cord Stimulation for Poststroke Spasticity (SCS-PSS)
Spinal Cord Stimulation for Poststroke Spasticity: a Multicentre, Double-blind, Randomised, Sham-controlled Trial (SCS-PSS)
The goal of this clinical trial is to learn whether spinal cord stimulation (SCS) is effective in treating post-stroke spasticity in adults. It will also evaluate the safety of the implanted SCS system. The main questions it aims to answer are:
- Does active SCS reduce limb spasticity compared with sham stimulation?
- What device-related problems do participants experience during the study?
All participants receive the same implantation and programming procedures,but no therapeutic stimulation(0 mA) for sham SCS group duringthe first 6 weeks after randomization.
Participants will:
- Have an SCS system surgically implanted
- Be randomly assigned to receive active SCS or sham SCS for 6 weeks
- After completion of the 6-week randomized comparison period, active stimulation will be initiated for all participants.
- Attend a post-operative visit within 3 to 7 days after surgery for device activation or sham activation, programming, safety checks, and study assessments
- Attend follow-up visits for study assessments at approximately 6, 12, 24 weeks, 1 year and 2 years after randomization
- Complete assessments of muscle spasticity, joint range of motion, motor function, walking ability, daily functioning, pain, and quality of life
- Report any medical problems or device-related problems during the study
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Post-stroke spasticity is a common disabling complication of ischemic or hemorrhagic stroke. It can lead to abnormal muscle tone, restricted joint movement, impaired motor function, pain, and reduced independence in daily activities. Current treatments include rehabilitation therapy, oral antispastic medications, and botulinum toxin injections, but some patients continue to have clinically significant spasticity despite these treatments. Spinal cord stimulation (SCS) is a neuromodulation technique that delivers electrical stimulation to the spinal cord and may help regulate abnormal spinal motor circuits and reduce spasticity.
Previous exploratory studies have suggested that SCS may reduce limb spasticity and improve muscle strength, motor coordination, and functional movement after stroke. However, the available evidence is mainly based on small or exploratory studies, and the safety and efficacy of SCS for post-stroke spasticity have not yet been confirmed in a large, randomized, sham-controlled clinical trial. Therefore, a well-designed controlled study is needed to determine whether the observed improvements are caused by active SCS and to further evaluate device-related safety.
The Spinal Cord Stimulation for Post-Stroke Spasticity study (SCS-PSS study) is a prospective, multicenter, double-blind, randomized, sham-controlled clinical trial designed to evaluate the safety and efficacy of an implanted SCS system for adults with post-stroke spasticity. The study will enroll 92 participants with stable unilateral upper- or lower-limb spasticity after ischemic or hemorrhagic stroke who have not achieved their treatment goals with previous treatments. All participants will undergo implantation of an SCS system and will then be randomized in a 1:1 ratio to receive either active SCS or sham SCS during the first 6 weeks after randomization. Participants will attend a postoperative visit within 3 to 7 days for active or sham device activation, programming, safety assessment, and study evaluations. At 6 weeks after randomization, all participants will receive active stimulation and will continue follow-up through 24 weeks. In addition, they will undergo long-term follow-up for up to 2 years to further evaluate the durability of treatment effects and the long-term safety of the implanted SCS system. The primary outcome is the change from baseline to 6 weeks after randomization in the mean Modified Ashworth Scale score of primary target muscle groups. Additional outcomes include joint range of motion, motor function, walking ability, functional independence, pain, quality of life, adverse events, serious adverse events, and device deficiencies.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Jianguang Sun
- Número de telefone: 010-60736388
- E-mail: sunjianguang@pinsmedical.com
Estude backup de contato
- Nome: Yifan Yang
- Número de telefone: 15674915048
- E-mail: yangyifan@pinsmedical.com
Locais de estudo
-
-
-
Beijing, China
- China-Japan Friendship Hospital
-
Contato:
- Qi Wang
- Número de telefone: 15810619158
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Aged ≥18 years and <75 years, regardless of sex;
- Diagnosed with ischemic or hemorrhagic stroke, with unilateral or single-limb motor dysfunction persisting for at least 6 months;
- The primary brain lesion and its underlying cause are clinically stable;
- Presence of unilateral upper- or lower-limb spasticity, with a Modified Ashworth Scale (MAS) grade of ≥2 in at least two muscle groups of the affected limb;
- Post-stroke limb dysfunction has not reached the treatment goal despite previous interventions, such as physical therapy and oral medications, and the participant's condition has shown no recent improvement;
- The type and dose of existing rehabilitation therapy and oral antispastic medications must remain unchanged during the study;
- Willing and able to complete all study visits and procedures;
- Able to understand the study and provide written informed consent.
Exclusion Criteria:
- Any contraindication to spinal cord stimulation surgery;
- Uncontrolled refractory epilepsy;
- Presence of tonic spasticity, such as decorticate rigidity or decerebrate rigidity;
- Poorly controlled severe psychiatric or cognitive impairment, defined as a Beck Depression Inventory-II score >25 or a Mini-Mental State Examination score <24;
- Active systemic infection;
- Presence of an implanted neurostimulator or drug delivery system;
- Botulinum toxin treatment within 4 months before enrollment;
- Plans to initiate any new treatment during the study that may affect limb movement, including chemical denervation therapies (such as botulinum toxin), oral antispastic medications, surgical procedures (such as peripheral neurotomy or contralateral C7 nerve transfer), or other physical therapy interventions;
- Pregnancy, breastfeeding, or planned pregnancy during the study;
- The participant or family is unable or unwilling to participate in long-term SCS treatment management;
- Participation in another clinical study within 4 weeks before signing informed consent;
- Any other condition that, in the investigator's judgment, makes the individual unsuitable for participation in the study.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: SCS Group
Active SCS
|
Participants will receive therapeutic electrical stimulation through the implanted spinal cord stimulation system beginning on Day 0, defined as the day of active or sham activation within 3-7 days after surgery.
An individualized SCS programming strategy will be used.
Initial stimulation parameters will include a frequency of 40-60 Hz, a pulse width of 200-300 μs, and a low starting amplitude that will be gradually increased according to participant tolerance.
For participants with concomitant conditions such as pain, the stimulation frequency may be increased as clinically appropriate.
Intermittent stimulation will be preferred, and electrode contact combinations will be individually selected.
Active stimulation will continue through the 24-week follow-up
|
|
Comparador Ativo: Control Group
Sham SCS
|
Participants will undergo the same implantation and programming procedures.
On Day 0, the implanted system will be turned on, but the stimulation amplitude will be set to 0 mA so that no effective electrical stimulation is delivered during the 6-week randomized comparison period.
After completion of the Week 6 assessment, participants will receive active SCS using the same individualized programming principles as the Active SCS Group.
Active stimulation will continue through the 24-week follow-up.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in Mean Modified Ashworth Scale Score of the Primary Target Muscle Groups From Baseline to Week 6
Prazo: Baseline to Week 6 after randomization
|
The primary outcome is the change in the mean Modified Ashworth Scale (MAS) score of the Primary Target Muscle Groups from baseline to Week 6. The Primary Target Muscle Groups are selected from a upper or lower limb before treatment and must include at least two muscle groups. For the upper limb, eligible muscle groups include the shoulder adductors, shoulder internal rotators, elbow flexors, elbow extensors, forearm pronators, wrist flexors, and finger flexors. For the lower limb, eligible muscle groups include the hip flexors, hip adductors, hip internal rotators, knee flexors, knee extensors, and ankle plantar flexors. For analysis, the original MAS grades are converted to a 0-5 numerical scale, with grade 1+ converted to 2 and grades 2, 3, and 4 converted to 3, 4, and 5, respectively. The mean MAS score is calculated across the selected Primary Target Muscle Groups. Change is calculated as the Week 6 mean MAS score minus the baseline mean MAS score. |
Baseline to Week 6 after randomization
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in Modified Ashworth Scale Scores of the Primary Target Muscle Groups From Baseline
Prazo: Day 0, Week 6, Week 12, Week 24, Year 1, and Year 2 after randomization
|
Change in MAS of the primary target muscle groups from baseline to day 0, week 6, week 12, week 24, 1 year and 2 years after randomization
|
Day 0, Week 6, Week 12, Week 24, Year 1, and Year 2 after randomization
|
|
Proportion of Participants With an Improvement in Mean Modified Ashworth Scale Score of at Least 1 Point
Prazo: Day 0, Week 6, Week 12, Week 24, Year 1, and Year 2 after randomization
|
A participant is defined as a responder when the mean MAS score of the Primary Target Muscle Groups decreases by at least 1 point compared with baseline.
The outcome is reported as the proportion of responders at each assessment.
|
Day 0, Week 6, Week 12, Week 24, Year 1, and Year 2 after randomization
|
|
Change in Active and Passive Joint Range of Motion From Baseline
Prazo: Day 0, Week 6, Week 12, Week 24, Year 1, and Year 2 after randomization
|
Active and passive range of motion are measured in degrees for movements corresponding to the assessed muscle groups.
Upper-limb measurements include shoulder abduction, shoulder external rotation, elbow extension, elbow flexion, forearm supination, wrist extension, and metacarpophalangeal joint extension.
Lower-limb measurements include hip extension, hip abduction, hip external rotation, knee extension, knee flexion, and ankle dorsiflexion.
A greater range generally indicates better joint mobility.
|
Day 0, Week 6, Week 12, Week 24, Year 1, and Year 2 after randomization
|
|
Change in Fugl-Meyer Assessment Score From Baseline
Prazo: Day 0, Week 6, Week 12, Week 24, Year 1, and Year 2 after randomization
|
The Fugl-Meyer Assessment (FMA) is used to assess motor and sensory function.
The upper-limb motor score ranges from 0 to 66, and the lower-limb motor score ranges from 0 to 34.
Light touch sensation is assessed at the upper arm, palm, thigh, and sole, with each site scored from 0 to 2, giving a total score of 0 to 8. Proprioception is assessed at the shoulder, elbow, wrist, thumb, hip, knee, ankle, and toe joints, with each site scored from 0 to 2, giving a total score of 0 to 16.
Higher scores indicate better motor and sensory function.
|
Day 0, Week 6, Week 12, Week 24, Year 1, and Year 2 after randomization
|
|
Change in Functional Independence Measure Score From Baseline
Prazo: Day 0, Week 6, Week 12, Week 24, Year 1, and Year 2 after randomization
|
The Functional Independence Measure (FIM) is used to assess functional independence.
The change in total FIM score from baseline is calculated at each post-baseline assessment.
A higher score indicates greater functional independence
|
Day 0, Week 6, Week 12, Week 24, Year 1, and Year 2 after randomization
|
|
Change in Physician Global Assessment Score From Baseline
Prazo: Day 0, Week 6, Week 12, Week 24, Year 1, and Year 2 after randomization
|
The Physician Global Assessment (PGA) is completed by the investigator to assess overall spasticity severity and treatment response.
The change in PGA score from baseline is calculated at each post-baseline assessment.
|
Day 0, Week 6, Week 12, Week 24, Year 1, and Year 2 after randomization
|
|
Change in 10-Meter Walk Test Performance From Baseline
Prazo: Day 0, Week 6, Week 12, Week 24, Year 1, and Year 2 after randomization
|
The 10-Meter Walk Test (10MWT) is used to assess comfortable and fast walking speed.
The change in walking time and walking speed from baseline is calculated at each post-baseline assessment.
A shorter walking time or higher walking speed indicates better walking performance.
|
Day 0, Week 6, Week 12, Week 24, Year 1, and Year 2 after randomization
|
|
Change in EQ-5D-5L Score From Baseline
Prazo: Day 0, Week 6, Week 12, Week 24, Year 1, and Year 2 after randomization
|
The EQ-5D-5L is used to assess health-related quality of life.
The change in the EQ-5D-5L health utility index and EQ-VAS score from baseline is calculated at each post-baseline assessment.
Higher scores indicate better health status.
|
Day 0, Week 6, Week 12, Week 24, Year 1, and Year 2 after randomization
|
|
Change in Visual Analogue Scale Score From Baseline
Prazo: Day 0, Week 6, Week 12, Week 24, Year 1, and Year 2 after randomization
|
Spasticity-related pain is assessed using a Visual Analogue Scale (VAS) ranging from 0 to 10.
The change in VAS score from baseline is calculated at each post-baseline assessment.
A lower score indicates less pain.
|
Day 0, Week 6, Week 12, Week 24, Year 1, and Year 2 after randomization
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Publicações e links úteis
Publicações Gerais
- Brashear A, Gordon MF, Elovic E, Kassicieh VD, Marciniak C, Do M, Lee CH, Jenkins S, Turkel C; Botox Post-Stroke Spasticity Study Group. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med. 2002 Aug 8;347(6):395-400. doi: 10.1056/NEJMoa011892.
- Rowald A, Komi S, Demesmaeker R, Baaklini E, Hernandez-Charpak SD, Paoles E, Montanaro H, Cassara A, Becce F, Lloyd B, Newton T, Ravier J, Kinany N, D'Ercole M, Paley A, Hankov N, Varescon C, McCracken L, Vat M, Caban M, Watrin A, Jacquet C, Bole-Feysot L, Harte C, Lorach H, Galvez A, Tschopp M, Herrmann N, Wacker M, Geernaert L, Fodor I, Radevich V, Van Den Keybus K, Eberle G, Pralong E, Roulet M, Ledoux JB, Fornari E, Mandija S, Mattera L, Martuzzi R, Nazarian B, Benkler S, Callegari S, Greiner N, Fuhrer B, Froeling M, Buse N, Denison T, Buschman R, Wende C, Ganty D, Bakker J, Delattre V, Lambert H, Minassian K, van den Berg CAT, Kavounoudias A, Micera S, Van De Ville D, Barraud Q, Kurt E, Kuster N, Neufeld E, Capogrosso M, Asboth L, Wagner FB, Bloch J, Courtine G. Activity-dependent spinal cord neuromodulation rapidly restores trunk and leg motor functions after complete paralysis. Nat Med. 2022 Feb;28(2):260-271. doi: 10.1038/s41591-021-01663-5. Epub 2022 Feb 7.
- Francisco GE, McGuire JR. Poststroke spasticity management. Stroke. 2012 Nov;43(11):3132-6. doi: 10.1161/STROKEAHA.111.639831. Epub 2012 Sep 13. No abstract available.
- Lorach H, Galvez A, Spagnolo V, Martel F, Karakas S, Intering N, Vat M, Faivre O, Harte C, Komi S, Ravier J, Collin T, Coquoz L, Sakr I, Baaklini E, Hernandez-Charpak SD, Dumont G, Buschman R, Buse N, Denison T, van Nes I, Asboth L, Watrin A, Struber L, Sauter-Starace F, Langar L, Auboiroux V, Carda S, Chabardes S, Aksenova T, Demesmaeker R, Charvet G, Bloch J, Courtine G. Walking naturally after spinal cord injury using a brain-spine interface. Nature. 2023 Jun;618(7963):126-133. doi: 10.1038/s41586-023-06094-5. Epub 2023 May 24.
- Creamer M, Cloud G, Kossmehl P, Yochelson M, Francisco GE, Ward AB, Wissel J, Zampolini M, Abouihia A, Berthuy N, Calabrese A, Loven M, Saltuari L. Intrathecal baclofen therapy versus conventional medical management for severe poststroke spasticity: results from a multicentre, randomised, controlled, open-label trial (SISTERS). J Neurol Neurosurg Psychiatry. 2018 Jun;89(6):642-650. doi: 10.1136/jnnp-2017-317021. Epub 2018 Jan 11.
- Gracies JM, Brashear A, Jech R, McAllister P, Banach M, Valkovic P, Walker H, Marciniak C, Deltombe T, Skoromets A, Khatkova S, Edgley S, Gul F, Catus F, De Fer BB, Vilain C, Picaut P; International AbobotulinumtoxinA Adult Upper Limb Spasticity Study Group. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double-blind randomised controlled trial. Lancet Neurol. 2015 Oct;14(10):992-1001. doi: 10.1016/S1474-4422(15)00216-1. Epub 2015 Aug 26.
- Riva N, Mora G, Soraru G, Lunetta C, Ferraro OE, Falzone Y, Leocani L, Fazio R, Comola M, Comi G; CANALS Study Group. Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2019 Feb;18(2):155-164. doi: 10.1016/S1474-4422(18)30406-X. Epub 2018 Dec 13.
- de Freitas RM, Bhatia S, Sorensen E, Verma N, Carranza E, Ensel S, Borda L, Boos A, Goldsmith J, Fisher LE, Fields DP, Powell MP, Gordon S, Balzer J, Friedlander RM, Wittenberg GF, Gerszten PC, Krakauer JW, Pirondini E, Weber DJ, Capogrosso M. Spinal cord stimulation for upper limb motor function in people with chronic post-stroke hemiparesis: a feasibility trial. Nat Med. 2026 Jun 4. doi: 10.1038/s41591-026-04435-1. Online ahead of print.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Manifestações Neurológicas
- Doenças musculoesqueléticas
- Distúrbios Cerebrovasculares
- Doenças Cerebrais
- Doenças do Sistema Nervoso Central
- Doenças do Sistema Nervoso
- Doenças Vasculares
- Doenças cardiovasculares
- Doenças Musculares
- Hipertonia muscular
- Manifestações Neuromusculares
- Condições Patológicas, Sinais e Sintomas
- Sinais e sintomas
- Espasticidade muscular
- Derrame
Outros números de identificação do estudo
- SCS-PNS0102&PINS-C2-01-53
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .